Skip to main content
SpringerLink
Log in

Translational medicine

Longer life for artificial joints

  • News & Views
  • Published:

From Nature

View current issue Submit your manuscript

Drug candidates that are related to a common metabolite called adenosine inhibit inflammation and reduce bone destruction in artificial joints. The finding suggests a potential approach to increasing the durability of prosthetic implants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Preventing the loosening of artificial joints.

References

  1. Teeny, S. M., York, S. C., Mesko, J. W. & Rea, R. E. J. Arthroplasty 18, 954–962 (2003).

    Article  Google Scholar 

  2. Purdue, P. E., Koulouvaris, P., Nestor, B. J. & Sculco, T. P. HSS J. 2, 102–113 (2006).

    Article  Google Scholar 

  3. Mediero, A. et al. Sci. Transl. Med. 4, 135ra65 (2012).

    Article  Google Scholar 

  4. Holt, G., Murnaghan, C., Reilly, J. & Meek, R. M. Clin. Orthop. Related Res. 460, 240–252 (2007).

    CAS  Google Scholar 

  5. Linden, J. Adv. Pharmacol. 61, 95–114 (2011).

    Article  CAS  Google Scholar 

  6. Murphree, L. J., Sullivan, G. W., Marshall, M. A. & Linden, J. Biochem. J. 391, 575–580 (2005).

    Article  CAS  Google Scholar 

  7. Ren, K. et al. Mol. Pharmaceut. 8, 1043–1051 (2011).

    Article  CAS  Google Scholar 

  8. Henson, P. M. Nature Immunol. 6, 1179–1181 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Joel Linden is in the Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.,

    Joel Linden

Authors
  1. Joel Linden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel Linden.

Ethics declarations

Competing interests

The author holds shares in Lewis and Clark Pharmaceuticals, LLC, a company that produces drugs targeting adenosine receptors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Linden, J. Longer life for artificial joints. Nature 487, 179–180 (2012). https://doi.org/10.1038/487179a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/487179a

  • Springer Nature Limited

Search

Navigation